[1] |
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria[J]. Allergy, 2018,73(7):1393⁃1414. doi: 10.1111/all.13397.
|
[2] |
中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南(2018版)[J]. 中华皮肤科杂志, 2019,52(1):1⁃5. doi: 10.3760/cma.j.issn.0412⁃4030.2019.01.001.
|
[3] |
于淼, 陈玉迪, 刘擘, 等. 中文版慢性荨麻疹生活质量问卷(CU⁃Q2oL)信效度验证[J]. 中华皮肤科杂志, 2020,53(12):992⁃997. doi: 10.35541/cjd.20200091.
|
[4] |
Dong W, An J, Geng P, et al. Years lost due to disability from skin diseases in China 1990⁃2017: findings from the Global Burden of Disease Study 2017[J]. Br J Dermatol, 2020,182(1):248⁃250. doi: 10.1111/bjd.18329.
|
[5] |
Jiao Q, Luo Y, Scheffel J, et al. Skin mast cells contribute to Sporothrix schenckii infection[J]. Front Immunol, 2020,11:469. doi: 10.3389/fimmu.2020.00469.
|
[6] |
Yu M, Song XT, Liu B, et al. The emerging role of mast cells in response to fungal infection[J]. Front Immunol, 2021,12:688659. doi: 10.3389/fimmu.2021.688659.
|
[7] |
Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know[J]. J Allergy Clin Immunol, 2017,139(6):1772⁃1781.e1. doi: 10.1016/j.jaci.2016.08.050.
|
[8] |
陈玉迪, 耿鹏, 赵嘉惠, 等. 慢性自发性荨麻疹:奥马珠单抗治疗作用机制与疗效评估[J]. 中华皮肤科杂志, 2019,52(9):652⁃655. doi: 10.3760/cma.j.issn.0412⁃4030.2019.09.014.
|
[9] |
陈玉迪, 刘擘, 宋晓婷, 等. 临界温度阈值检测在冷接触性荨麻疹中的临床应用[J]. 中华皮肤科杂志, 2020,53(5):352⁃355. doi: 10.35541/cjd.20190840.
|
[10] |
Zhao Z, Reimann S, Wang S, et al. Ordinary vibratory angioedema is not generally associated with ADGRE2 mutation[J]. J Allergy Clin Immunol, 2019,143(3):1246⁃1248.e4. doi: 10.1016/j.jaci.2018.10.049.
|
[11] |
宋晓婷, 刘擘, 陈玉迪, 等. 奥马珠单抗治疗27例人工荨麻疹回顾分析[J]. 中华皮肤科杂志, 2021,54(12):1092⁃1096. doi: 10.35541/cjd.20210473.
|
[12] |
赵作涛. 诱导性荨麻疹治疗的选择[J]. 皮肤病与性病, 2015,37(1):19.
|
[13] |
Chen YD, Maurer M, Yu M, et al. Addition of omalizumab to antihistamine treatment in chronic urticaria: a real⁃world study in China[J]. Ann Allergy Asthma Immunol, 2020,125(2):217⁃219. doi: 10.1016/j.anai.2020.04.026.
|
[14] |
Chen Y, Yu M, Huang X, et al. Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both[J]. World Allergy Organ J, 2021,14(1):100501. doi: 10.1016/j.waojou.2020.100501.
|
[15] |
Song XT, Chen YD, Yu M, et al. Omalizumab in children and adolescents with chronic urticaria: a 16⁃week real⁃world study[J]. Allergy, 2021,76(4):1271⁃1273. doi: 10.1111/all.14686.
|
[16] |
Yu M, Terhorst⁃Molawi D, Altrichter S, et al. Omalizumab in chronic inducible urticaria: a real⁃life study of efficacy, safety, predictors of treatment outcome and time to response[J]. Clin Exp Allergy, 2021,51(5):730⁃734. doi: 10.1111/cea.13838.
|
[17] |
宋晓婷, 刘擘, 陈玉迪, 等. 奥马珠单抗治疗慢性自发性荨麻疹的疗效及安全性分析[J]. 中华皮肤科杂志, 2021,54(12):1063⁃1070. doi: 10.35541/cjd.20210324.
|
[18] |
于淼, 陈玉迪, 刘擘, 等. 中文版慢性荨麻疹生活质量问卷(CU⁃Q2oL)信效度验证[J]. 中华皮肤科杂志, 2020,53(12):992⁃997. doi: 10.35541/cjd.20200091.
|
[19] |
于淼, 陈玉迪, 刘擘, 等. 中文版荨麻疹控制评分量表及信效度验证[J]. 中华皮肤科杂志, 2020,53(7):533⁃538. doi: 10. 35541/cjd.20191190.
|
[20] |
于淼, 陈玉迪, 刘擘, 等. 慢性自发性荨麻疹的临床评估体系[J]. 中华皮肤科杂志, 2021,53(12):1117⁃1121. doi: 10.35541/cjd.20210379.
|
[21] |
Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria[J/OL]. Allergy,2021(2021⁃09⁃18). doi: 10.1111/all. 15090.[published online ahead of print]
|
[22] |
陈玉迪, 耿鹏, 涂平, 等. 抗组胺药物在变态反应性疾病中的应用[J]. 临床药物治疗杂志, 2019,17(1):23⁃26. doi: 10.3969/j.issn.1672⁃3384.2019.01.006.
|
[23] |
Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta⁃analysis of randomized clinical trials[J]. J Allergy Clin Immunol, 2016,137(6):1742⁃1750.e4. doi: 10.1016/j.jaci.2015.12.1342.
|
[24] |
Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria[J]. N Engl J Med, 2013,368(10):924⁃935. doi: 10.1056/NEJMoa121 5372.
|
[25] |
Ertas R, Ozyurt K, Atasoy M, et al. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change[J]. Allergy, 2018,73(3):705⁃712. doi: 10.1111/all.13345.
|
[26] |
Sussman G, Hébert J, Gulliver W, et al. Omalizumab re⁃treatment and step⁃up in patients with chronic spontaneous urticaria: OPTIMA trial[J]. J Allergy Clin Immunol Pract, 2020,8(7):2372⁃2378.e5. doi: 10.1016/j.jaip.2020.03.022.
|
[27] |
Kaplan AP, Joseph K, Maykut RJ, et al. Treatment of chronic autoimmune urticaria with omalizumab[J]. J Allergy Clin Immunol, 2008,122(3):569⁃573. doi: 10.1016/j.jaci.2008.07.006.
|
[28] |
Maurer M, Eyerich K, Eyerich S, et al. Urticaria: Collegium Internationale Allergologicum (CIA) update 2020[J]. Int Arch Allergy Immunol, 2020,181(5):321⁃333. doi: 10.1159/000507218.
|
[29] |
Tontini C, Marinangeli L, Cognigni M, et al. Omalizumab in chronic spontaneous urticaria: patient⁃tailored tapering or planned discontinuation?[J]. Ann Allergy Asthma Immunol, 2015,115(2):147⁃148. doi: 10.1016/j.anai.2015.05.005.
|
[30] |
Türk M, Maurer M, Yılmaz İ. How to discontinue omalizumab in chronic spontaneous urticaria?[J]. Allergy, 2019,74(4):821⁃824. doi: 10.1111/all.13675.
|
[31] |
Türk M, Carneiro⁃Leão L, Kolkhir P, et al. How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers[J]. J Allergy Clin Immunol Pract, 2020,8(1):113⁃124. doi: 10.1016/j.jaip.2019.07.021.
|
[32] |
Staubach P, Peveling⁃Oberhag A, Lang BM, et al. Severe chronic spontaneous urticaria in children ⁃ treatment options according to the guidelines and beyond ⁃ a 10 years review[J]. J Dermatolog Treat, 2020:1⁃4. doi: 10.1080/09546634.2020.1782326.
|
[33] |
Namazy JA, Blais L, Andrews EB, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease⁃matched comparator cohort[J]. J Allergy Clin Immunol, 2020,145(2):528⁃536.e1. doi: 10.1016/j.jaci.2019.05.019.
|
[34] |
Liao SL, Yu M, Zhao ZT, et al. Case report: omalizumab for chronic spontaneous urticaria in pregnancy[J]. Front Immunol, 2021,12:652973. doi: 10.3389/fimmu.2021.652973.
|